Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israel’s NeuroDerm Acquired by Japanese Company for Record-Setting $1.1 Billion
Error: Contact form not found.
by JNS.org
The NeuroDerm website. Photo: NeuroDerm.
JNS.org – Japan’s Mitsubishi Tanabe Pharma Corporation (MTPC) acquired the Israeli pharmaceutical company NeuroDerm for $1.1 billion this week, in the largest-ever acquisition of an Israeli healthcare company.
The deal is part of MTPC’s business strategy to grow its US-based operations, and was agreed upon unanimously by NeuroDerm’s board of directors.
The Israeli pharmaceutical company specializes in developing new drug delivery methods and devices for central nervous system disorders, and hopes to launch two new groundbreaking products during the next two years.
“We believe that this transaction will yield important benefits for NeuroDerm’s shareholders and the Parkinson’s disease patients that urgently need new therapies,” said NeuroDerm CEO Dr. Oded Lieberman.
“MTPC has demonstrated development and commercialization expertise in the field of neurology and we are confident that the combination of their resources and the robust data…will help make this important new therapy available as broadly and rapidly as possible,” he added.
